Browsing Tag
India
4532 posts
Can Titan Company (NSE: TITAN) justify its post-Q4 rally?
TITAN has growth, brands and gold demand on its side. The harder question is whether FY27 earnings can justify a stock near record highs.
REA Group (ASX: REA) shares jump as Q3 FY2026 result lifts cost guidance and confirms residential recovery
REA Group fell 9.6% on H1 results in February. Today's Q3 print rewrites that thesis. Listing volumes are back, yield is at 14%, costs are being held.
Oil markets face fresh volatility as US and Iran fighting threatens supply confidence
Brent crude is back above $100. United States and Iran tensions have turned Strait of Hormuz risk into the market’s key inflation threat.
Adani Ports breaks out at record Rs 1,747 as 500 MMT milestone meets Hormuz reroute trade (NSE: ADANIPORTS)
The Strait of Hormuz is running at 5% of pre-war traffic. Adani Ports just printed a record â‚ą1,747. The two stories are the same story.
SIS Limited (NSE: SIS) reports record FY26 as PAT rises 28% and labour code reset comes into view
SIS Limited has record FY26 numbers. The bigger test is whether labour reforms can turn scale into stronger margins.
Unilever PLC (LSE: ULVR) reports 3.8% underlying sales growth as Dove, India and Home Care drive Q1
Unilever volumes are recovering, but currency and portfolio risk remain. Can ULVR turn simplification into a cleaner growth story?
Mphasis posts 14.4% Q4 revenue jump and 68% TCV surge as AI-led deals rebuild the growth narrative
Mphasis posted 68% TCV jump and 14.4% Q4 revenue growth, but MPHASIS stock sits near 52-week low. Will FY27 conversion vindicate the AI-led repositioning?
Coca-Cola (KO) lifts 2026 EPS guidance after Q1 beat as price/mix slows and APAC operating income falls 14%
Coca-Cola raised 2026 EPS guidance after a Q1 beat. The harder question is whether tax cuts and a calendar tailwind are masking slower pricing power.
Prudential plc Q1 2026 update shows Asia insurance growth is still doing the heavy lifting
Prudential’s Asia growth is intact, but PRU shares slipped. The bigger test is whether margins and buybacks can keep investors patient.
Haleon (HLN) Q1 2026 results: Can Sensodyne and parodontax offset weak cold and flu demand?
Haleon’s cold and flu drag is testing growth. Sensodyne, parodontax and margin discipline may decide whether HLN can regain momentum.